Skip to search formSkip to main contentSkip to account menu

Trastuzumab VC-seco-DUBA

Known as: ADC SYD985, Antibody-drug Conjugate SYD985, SYD985 
An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
While the global cancer burden is still high with 10 million people being diagnosed with cancer and 6 million cancer-related… 
2018
2018
The Kenya-Ethiopia border has for long been a security problem for the northern Kenya districts of Marsabit and Moyale since… 
2017
2017
Background: SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and a cleavable linker-duocarmycin (vc… 
2015
2015
Introduction: Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer which carries an extremely poor… 
2015
2015
SYD985 is a novel anti-HER2 antibody-drug conjugate (ADC) in development for breast cancer. The ADC consists of three parts: i… 
2015
2015
SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, Synthon9s proprietary cleavable linker-duocarmycin payload… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA We have built a linker-drug platform based on a cleavable… 
2014
2014
SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon9s proprietary cleavable linker-duocarmycin payload. The…